drugset / Trial / NCT02727621

Dexmedetomidine Sedation and Cardiopulmonary Bypass

NCT02727621

Phase 2 Completed 100 enrolled Assiut University
RandomizedParallel-groupDouble-blindTreatment

Summary

Dexmedetomidine is a unique sedative anesthetic agent that allows accurate control of the depth of sedation and provides analgesia, cardio protection, renal protection, and neuroprotection without causing respiratory depression. It is an alpha 2-adrenoreceptor agonist that modulates the release of catecholamines from the central and autonomic nervous systems. When patients sedated by dexmedetomidine are allowed to become responsive, they are calm and cooperative (1). No other sedative agent has this feature, and sedated patients frequently awaken in a confused state. Investigators are conducting this study project to compare between dexmedetomidine based and propofol based anesthetic techniques with regard to hemodynamic changes, stress hormone release as well as cytokines in patients undergoing CPB for coronary revascularization.

Timeline

Start
2016-04
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.5 ug/kg
Comparator Dexmedetomidine Other / unclassified 0.7 ug/kg
Comparator Propofol Small molecule 50 ug/kg
Comparator Propofol Small molecule 100 ug/kg

Indications

No indication recorded.